Skip to content
NAICS 2022 541714 54171 ↗
● Official Registry Data: 2026-11-19

541714 — Research and Development in Biotechnology (except Nanobiotechnology)

NAICS 2022 541714 (Research and Development in Biotechnology (except Nanobiotechnology)) classifies within economic division 72 (NACE Rev), linking EU/UN activity boundaries with US NAICS, UK SIC, and national regulatory obligations.

01 / Standard & Revision
NAICS 2022

U.S. Census Bureau • v2022

02 / Parent Hierarchy
54171

Research and Development in the Physical, Engineering, and Life Sciences

03 / Mapped Standards
4

ISIC 7210

04 / Subclasses & Scope
1 Items

MCC 8731

01 / OFFICIAL SCOPE & OPERATORS

Activity Scope, Operators & Exclusions

Who Uses This Code & Typical Business Models

  • Biotech, pharma discovery, AI/quantum, materials, and engineering R&D firms (72.10)
  • Contract Research Organizations (CROs), university spinouts, and deep-tech labs
  • Social sciences, humanities, and policy research institutes (72.20)

This Class Includes

1
  • This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.

Official Census Illustrative Examples

  • Cloning research and experimental development laboratories
  • DNA technologies (e.g., microarrays) research and experimental development laboratories
  • Nucleic acid chemistry research and experimental development laboratories
  • Protein engineering research and experimental development laboratories
  • Recombinant DNA research and experimental development laboratories

This Class Excludes (Cross-References)

0

—

02 / REGULATORY & TAX DOSSIER

Legislation, Licensing, Incorporation & Tax Framework

Div. 72 • Sec. N

Governing Statutes & Regulations

R&D & Design Incentives Law No. 5746 Technology Development Zones Law No. 4691 (Teknokent) Industrial Property Law No. 6769 (Patents & Employee Inventions) OHS & Biosafety Regulations

Mandatory Permits, Licenses & Authorities

  • No license required for desk/theoretical R&D; Law 5746 R&D Center certification requires 15–30+ FTE researchers inside dedicated facilities.
  • Clinical trials (CROs) require TİTCK Clinical Research Approval; genetic/biosafety labs follow Law No. 5977 & Biosafety regulations.

Incorporation Route & Chamber Registration

EU NACE Rev. 2.1 Framework
NACE Rev. 2.1 merged 72.11 Biotech & 72.19 into unified 72.10! EU entities access Horizon Europe grants, OECD Frascati Manual R&D standards, and Clinical Trials Reg. (EU) 536/2014.
United States (IRS / SBA / NAICS)
Maps to NAICS 5417. Deep-tech labs tap federal SBIR/STTR non-dilutive grants and IRS IRC § 41 R&D Tax Credit (allowing eligible startups up to $500k/yr payroll-tax offset alongside § 174 rules).
United Kingdom (Companies House / HMRC)
Directly unlocks UK R&D Intensive SME Relief (ERIS) cash tax credits, the 10% UK Patent Box, and Innovate UK grants under UK SIC 72xxx.

VAT, Withholding & Statutory Incentives

  • MAXIMUM TAX RELIEF STACK: Eligible R&D spending unlocks 100% Super-Deduction + 80–95% Payroll Income-Tax Withholding Relief + 50% SGK Employer Share subsidy under Law 5746, plus Teknokent Law 4691 100% profit exemption and 50% Patent Box exemption (KVK Art. 5/B)!
  • Eligible for KOSGEB Business Development (1.5M+ TL) and TÜBİTAK TEYDEB / 1512 BİGG non-dilutive R&D grants.

Cross-Border Regulatory Frameworks (EU / US / UK)

TR • Corporate & Tradesmen Registry

Chamber of Commerce or Industry — Corporate entity standard for R&D grants, patent ownership, and VC equity.

EU / Global Technical Alignment

NACE Rev. 2.1 merged 72.11 Biotech & 72.19 into unified 72.10! EU entities access Horizon Europe grants, OECD Frascati Manual R&D standards, and Clinical Trials Reg. (EU) 536/2014.

AUDIT & BOUNDARY CHECK

Classification Boundaries & Audit Risks

  • Routine QA/certification testing belongs in 71.20, and commercial market polling sits in 73.20 — NOT Div. 72 R&D.
  • Commercializing an invented product into mass manufacturing requires adding the applicable Div. 10–32 production code alongside R&D.
04 / INTERNATIONAL CROSSWALK & MCC

Global Classification Passport

Verified structural and concordance mappings across EU, US, UK, UN, and national registries.

Payment Processing & ISO 18245 MCC Profile

Visa / Mastercard ISO 18245
MCC 8731
Low Risk Tier
Testing Laboratories (Non-Medical) & R&D

Low-risk B2B laboratory, certification, and contract R&D billing.

05 / BOUNDARIES & COMPARISON

Critical Distinctions & Sibling Codes

Open Full Comparison Tool →

Critical Regulatory & Scope Boundaries vs. Adjacent Codes

Critical Regulatory & Scope Boundaries vs. Adjacent Codes
Compared CodeScope BoundaryRegulatory & Tax Impact
62.10 — Software Engineering → Fundamental experimental science/deep-tech discovery is 72.10; commercial software app delivery is 62.10.Both enjoy high-tech priority; wet labs trigger biosafety/clinical approvals.
541714 vs 541110

541110 — Offices of Lawyers

This industry comprises offices of legal practitioners known as lawyers or attorneys (i.e., counselors-at-law) primarily engaged in the practice of law. Establishments in this industry may provide expertise in a range or in spe...

06 / TAXONOMY TREE

Classification Hierarchy & Data Export

07 / FAQ

Frequently Asked Questions

What business activities and models fall under NAICS 2022 541714?

541714 (Research and Development in Biotechnology (except Nanobiotechnology)): This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.. Typical operators: Biotech, pharma discovery, AI/quantum, materials, and engineering R&D firms (72.10); Contract Research Organizations (CROs), university spinouts, and deep-tech labs.

What regulatory licensing and tax rules apply to 541714 across EU, US, UK, or Turkey?

EU: NACE Rev. 2.1 merged 72.11 Biotech & 72.19 into unified 72.10! EU entities access Horizon Europe grants, OECD Frascati Manual R&D standards, and Clinical Trials Reg. (EU) 536/2014. US: Maps to NAICS 5417. Deep-tech labs tap federal SBIR/STTR non-dilutive grants and IRS IRC § 41 R&D Tax Credit (allowing eligible startups up to $500k/yr payroll-tax offset alongside § 174 rules). UK: Directly unlocks UK R&D Intensive SME Relief (ERIS) cash tax credits, the 10% UK Patent Box, and Innovate UK grants under UK SIC 72xxx.

How does 541714 differ legally from 62.10 (62.10 — Software Engineering)?

Fundamental experimental science/deep-tech discovery is 72.10; commercial software app delivery is 62.10. Regulatory impact: Both enjoy high-tech priority; wet labs trigger biosafety/clinical approvals.

What are the international classification equivalents and MCC code for 541714?

Verified concordance for 541714: UN ISIC Rev. 5: 7210 • Payment MCC 8731 (Testing Laboratories (Non-Medical) & R&D).